CAF方案新辅助化疗对乳腺癌组织BCSG1蛋白表达的影响(英文)

目的探讨CAF联合化疗方案的新辅助化疗对乳腺癌组织BCSG1蛋白表达的影响。方法采用免疫组化SP法分别检测34例行CAF联合方案新辅助化疗患者(新辅助化疗组)和同期110例未行新辅助化疗患者(对照组)手术切除的乳腺癌组织BCSG1蛋白表达。同时对新辅助化疗组疗效进行病理形态学评价,并分析BCSG1蛋白表达与病理形态学变化的关系。结果新辅助化疗组化疗总有效率为79．4％。新辅助化疗组BCSG1蛋白高表达率明显低于对照组(29．4％比64．5％,P<0．01),化疗后部分缓解(Ⅱ级)病例BCSG1蛋白高表达水平明显低于无效(Ⅲ级)病病(P=0．002)。结论采用CAF方案新辅助化疗近期疗效明显,可抑制乳腺癌BCSG1蛋白的表达。

Effect of Neoadjuvant CAF Regimen on the Expression of BCSG1 in Breast Cancer*

Objective: To evaluate the efficacy of neoadjuvant chemotherapy and explore a sensitive and objective way in the evaluation of neoadjuvant chemotherapy, the pathological changes and BCSG1 expression were studied by pathological and immunohistochemical method in breast cancer patients with CAF neoadjuvant chemotherapy (Cyclophosphamide, Adriamycin and Fluorouracil, CAF) and those without at the same period. Methods: Specimens were obtained from 34 breast cancer patients receiving neoadjuvant CAF regimen chemotherapy (CAF group) and 110 breast cancer patients not receiving neoadjuvant chemotherapy (control group). The BCSG1 expression was detected by SP immunohistochemistry. Correlation between BCSG1 expression and pathological response to CAF neoadjuvant chemotherapy was analyzed. Results: Overall response rate to neoadjuvant chemotherapy was 79.4%. The strong cytoplasm expression of BCSG1 was significantly lower in CAF group than in control group (29.4% vs. 64.5%, P<0.01). In CAF group, the positive cytoplasm expression in partial response (PR) (grade n) cases was significantly lower than that in no response (NR) (grade III) cases (P=0.002). Conclusion: Neoadjuvant chemotherapy of CAF regimen could decrease the nuclear expression of BSCG1 in breast cancer.